QSTAR ELITE PRO HIGH PERFORMANCE QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETER

描述（由申请人提供）：蛋白质组学的进步为心血管研究提供了前所未有的机会。新泽西医学和牙科大学（UMDNJ）-新泽西医学院（NJMS）细胞生物学和分子医学系心血管研究所（CVRI）致力于了解心血管疾病的细胞和分子机制。CVRI目前正从NIH获得总额为4400万美元的资金。蛋白质组学的发现构成了我们的研究战略的一个组成部分。为了实现我们的NIH特定目标，包含蛋白质组学组件，我们已经建立了一个心脏蛋白质组学研究小组的指导下，这PI。CVRI已成为UMDNJ高级蛋白质组学研究中心（CAPR）的设备，特别是质谱仪的主要用户之一。我们的蛋白质组学实验大多采用基于二维凝胶电泳（2DE）的方法。然而，这种方法有其局限性，不能检测低丰度，高疏水性，极端等电点和高分子量的蛋白质。最近，一个新兴的技术，iTRAQ，已被优化，并实施在CAPR定量鸟枪蛋白质组学。它已被证明在扩大蛋白质组覆盖范围和鉴定低丰度蛋白质方面更有效。然而，这种技术在每次实验的基础上需要大量的仪器时间。由于不同研究小组的需求不断增长，特别是UMDNJ-NJMS的神经科学（NeuroProteomics Core Facility）和癌症研究（新成立的癌症中心），CAPR现有的质谱仪非常有限。因此，为了实现我们的目标，我们建议购买一台具有高速MALDI源的QSTAR（r）Elite质谱仪，它为iTRAQ实验和低丰度蛋白质的鉴定提供了更快的速度，补充了现有的质谱仪。这台新的质谱仪将设在CAPR，该中心将于2006年9月搬迁到NJMS大学医院癌症中心大楼。一个由CVRI、CAPR和NJMS-UH癌症中心研究人员组成的咨询委员会将监督该仪器的财政预算、科学管理和日常运作。用户俱乐部将为数据共享和协作提供一个重要论坛。借助新的QSTAR（r）Elite系统，UMDNJ的心血管研究人员可以使用最先进的蛋白质组学技术来最大限度地发挥其优势，以补充其现有的研究方法，并促进新的研究方向和合作。

DESCRIPTION (provided by applicant): Advances in proteomics have provided unprecedented opportunities for cardiovascular research. The Cardiovascular Research Institute (CVRI) in the Department of Cell Biology and Molecular Medicine at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School (NJMS) are dedicated to the understanding of cellular and molecular mechanisms in cardiovascular diseases. CVRI is currently receiving funding from the NIH totaling 44 million dollars. Proteomic discoveries constitute an integral component of our research strategy. To accomplish our NIH specific aims containing proteomics components, we have established a cardiac proteomics research group under the direction of this PI. CVRI has become one of the major users of equipments, especially mass spectrometers in the Center of Advanced Proteomics Research (CAPR) of UMDNJ. Most of our proteomics experiments have conducted by 2D gel electrophoresis (2DE)-based approach. However, this approach has its limitation, not able to detect proteins of low abundance, high hydrophobicity, extreme isoelectric points, and high molecular weights. Recently, an emerging technology, iTRAQ, has been optimized and implemented in CAPR for quantitative shotgun proteomics. It has been proven more effective in expanding the proteome coverage and identifying low abundant proteins. This technology however, requires significant instrument time on a per experiment basis. Access to the existing mass spectrometers in CAPR is extremely limited due to the growing demands from different research groups, especially neuroscience (NeuroProteomics Core Facility) and cancer research (newly established Cancer Center) at UMDNJ-NJMS. Therefore, to fulfill our aims, we propose to purchase a QSTAR(r) Elite mass spectrometer with high speed MALDI source, which provides greater speed for iTRAQ experiments and identification of low abundant proteins, complementing existing mass spectrometers. This new mass spectrometer will be located in CAPR, which will be relocated to the NJMS-University Hospital Cancer Center Building, opening in September 2006. An advisory committee composed of CVRI, CAPR, and NJMS-UH Cancer Center investigators, would oversee the fiscal budget, scientific management, and daily operation of this instrument. A User Club would provide an important forum for data sharing and collaborations. With the benefit of a new QSTAR(r) Elite system, cardiovascular investigators at UMDNJ could use the state-of-the-art proteomics technology to maximize their benefits in complementing their existing research approaches and promoting new research directions and collaborations.